Carcinoma, Ovarian Epithelial: all 1,619 studies
Page 8 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.Status unknownNCT04661696Phase 2
- CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 1
- Cell-free DNA Methylation for Epithelial Ovarian CancerStatus unknownNCT04651946Phase 2
- A Training Set for the HRD Model in EOCStatus unknownNCT04651933
- A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian CancerCompletedNCT04651920
- A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS MutationActive, not recruitingNCT04625270Phase 2
- Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginStatus unknownNCT04620954Phase 1/2
- Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life StudyStatus unknownNCT04617470
- A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian CancerTerminatedNCT04614051Phase 1
- Risk Factors for Anatomic Leakage in Advanced Ovarian Cancer SurgeryCompletedNCT04604964
- Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian CancerStatus unknownNCT04590625Phase 2
- The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian CancerStatus unknownNCT04582552
- Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.CompletedNCT04573933
- Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerStatus unknownNCT04566952Phase 2
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian CancerTerminatedNCT04562298Phase 1
- To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian CancerWithdrawnNCT04561817Phase 2
- Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian CancerStatus unknownNCT04556539Phase 2
- Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian CancerStatus unknownNCT04556071Phase 2
- Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoidsStatus unknownNCT04555473
- Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian CancerCompletedNCT04546373
- Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian CancerWithdrawnNCT04542603Phase 1
- Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer PatientsCompletedNCT04537702Not applicable
- A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer PatientsCompletedNCT04517357Phase 2
- Deep Learning Magnetic Resonance Imaging Radiomic Predict Platinum-sensitive in Patients With Epithelial Ovarian CancerStatus unknownNCT04511481
- Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch SyndromeTerminatedNCT04508764Not applicable
- Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian CancerActive, not recruitingNCT04507841Phase 2
- Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian CancerStatus unknownNCT04507750Not applicable
- 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological FindingsStatus unknownNCT04504110Phase 2
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1
- Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryActive, not recruitingNCT04498117Phase 3
- Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 MutationStatus unknownNCT04489706Not applicable
- A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR MutationStatus unknownNCT04473339Phase 3
- STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the NetherlandsActive, not recruitingNCT04470921
- Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2CompletedNCT04461457Early Phase 1
- Exemestane in Hormone Receptor Positive High Grade Ovarian CancerTerminatedNCT04460807Phase 3
- Efficacy of Letrozole in Recurrent Ovarian CancerTerminatedNCT04421547Phase 3
- Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian CancerCompletedNCT04417192Phase 2
- Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & SurvivalStatus unknownNCT04402333
- Effect of Hemp-CBD on Patients With CIPNStatus unknownNCT04398446Phase 2
- First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2bTerminatedNCT04396340Phase 1
- OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)WithdrawnNCT04389229Phase 1/2
- Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04383977Phase 2
- Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04376073Phase 2
- Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian CancerCompletedNCT04360629Not applicable
- Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04348032Phase 2
- Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian CancerStatus unknownNCT04337632Phase 3
- Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian CancerStatus unknownNCT04300699Not applicable
- Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant SettingCompletedNCT04284852Phase 2
- HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC)Status unknownNCT04280185Not applicable
- Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE)Status unknownNCT04279509Not applicable
- ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerTerminatedNCT04267939Phase 1
- NUVOLA TRIAL Open-label Multicentre StudyStatus unknownNCT04261465Phase 2
- Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) in Epithelial Ovarian CancerStatus unknownNCT04257786Not applicable
- CINSARC Genomic Signature as Predictor of Resectability of Ovarian AdenocarcinomaCompletedNCT04248231
- A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid MalignanciesTerminatedNCT04244552Phase 1
- A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.WithdrawnNCT04239014Phase 2
- HIPEC in Ovarian Cancer, Case-Controls Study With 10-years Follow upCompletedNCT04234243
- A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyStatus unknownNCT04229615Phase 3
- Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsCompletedNCT04227522Phase 3
- Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer PatientsCompletedNCT04222465
- Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian CancerStatus unknownNCT04217798Phase 2
- Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging AlgorithmStatus unknownNCT04214782Not applicable
- Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric PatientsTerminatedNCT04213794Early Phase 1
- Genetic Mutation in Epithelial Ovarian CancerStatus unknownNCT04191252
- Homologous Recombination Deficiency Status in Epithelial Ovarian CancerStatus unknownNCT04190667
- Diagnosing Ovarian Cysts - the DOC StudyCompletedNCT04188652
- Bevacizumab and Tocotrienol in Recurrent Ovarian CancerCompletedNCT04175470Phase 2
- Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant ChemotherapyTerminatedNCT04163094Phase 1
- Real-life Data of Olaparib in Relapsed Ovarian Cancers PatientsCompletedNCT04152941
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Phase 1/2
- Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian CancerCompletedNCT04135521
- Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian CancerStatus unknownNCT04101760Phase 3
- Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational StudyStatus unknownNCT04091204Phase 2
- Adoptive T Cell Therapy in Patients With Recurrent Ovarian CancerStatus unknownNCT04072263Phase 1/2
- Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian CancerStatus unknownNCT04068974Phase 2
- Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerCompletedNCT04067960Early Phase 1
- Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)Status unknownNCT04055038Phase 2/3
- Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on HemodynamicsCompletedNCT04032600Not applicable
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerStatus unknownNCT04029909Phase 1
- Genomic BRCA and Extensive ovArian Cancer TestingCompletedNCT04027868
- Tri Association in Patient With Advanced Epithelial Ovarian Cancer in RelapseStatus unknownNCT04015739Phase 2
- Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04000295Phase 3
- A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian CancerCompletedNCT03989336Phase 2
- Role of Surgery in Advanced Ovarian CancerCompletedNCT03980028
- Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian CancerActive, not recruitingNCT03949283Phase 3
- CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer PatientsTerminatedNCT03944902Phase 1
- Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT03942068Phase 2
- Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)CompletedNCT03940196Phase 3
- Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian CancerCompletedNCT03936270Phase 2
- Evaluation and Treatment of Iron Deficiency in Ovarian Cancer PatientsTerminatedNCT03933813Phase 1/2
- Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or ChemotherapyWithdrawnNCT03933761Phase 2
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2)CompletedNCT03931304
- Anlotinib for Patients With Platinum Resistant or Refractory Ovarian CancerStatus unknownNCT03924882Phase 2
- The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian CancerCompletedNCT03921658
- MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian CancerStatus unknownNCT03916679Phase 1/2
- Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerActive, not recruitingNCT03907527Phase 1
- Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological CancerWithdrawnNCT03902379Not applicable
- Chiauranib in Combination With Chemotherapy in Patients With Ovarian CancerCompletedNCT03901118Phase 2
- A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)Status unknownNCT03899610Phase 2
- A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerStatus unknownNCT03895788Phase 1